The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
FUDANZHANGJIANG Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.46% HKD2.15
America/New_York / 3 mai 2024 @ 03:57
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 700.90 mill |
| EPS: | 0.110 |
| P/E: | 19.55 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 326.00 mill |
| Avg Daily Volume: | 0.666 mill |
| RATING 2024-05-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.56x |
| Company: PE 19.55 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.49x |
| Company: PE 19.55 | industry: PE 13.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD3.08 (43.05%) HKD0.926 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 2.08 - 2.20 ( +/- 2.80%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD2.15 (-0.46% ) |
| Volume | 0.0780 mill |
| Avg. Vol. | 0.666 mill |
| % of Avg. Vol | 11.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 1349.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
1349.HK
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.